eligibility_summary
Adults ≥60 or 50–59 with HCT-CI ≥3, hematologic malignancy (not MPS/MDS), ≤35 days after first haploidentical peripheral blood allo-HSCT with Baltimore conditioning (Flu/Cy/TBI) and standard GVHD prophylaxis (PTCy, CsA, MMF), discharged from aplasia ≤35 days, consent, social security. Exclude: prior allo/organ transplant, GVHD, Thymoglobuline contraindication/rabbit allergy, pregnancy/breastfeeding, emergency, inability to consent or follow-up, legal protection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
NCT06066255 tests post-aplasia low-dose Thymoglobulin to reinforce GVHD prophylaxis after haploidentical allo-HSCT. Intervention: Thymoglobulin (rabbit anti-thymocyte globulin, polyclonal IgG anti-lymphocytic serum), single IV 1 mg/kg 48–72 h after emergence from aplasia. Mechanism: broad anti-T-cell antibody binding (e.g., CD2/CD3/CD4/CD8/HLA-DR) causing T-cell depletion via complement-dependent cytotoxicity and apoptosis, Fc-mediated clearance, and immune modulation (reduces alloreactive effector T cells, may favor Tregs), also impacts B cells, NK cells, and dendritic cells. Target cells/pathways: donor/recipient T lymphocytes driving alloreactivity and TCR/NFAT-dependent activation, complements cytotoxic pathways. Background SOC (not under test): PTCy (kills proliferating alloreactive T cells), cyclosporine (calcineurin/NFAT inhibitor), mycophenolate (IMPDH inhibitor).